TY - JOUR T1 - Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19 JF - medRxiv DO - 10.1101/2020.11.03.20216580 SP - 2020.11.03.20216580 AU - Sara Schumann AU - Astrid Kaiser AU - Ferdinando Nicoletti AU - Katia Mangano AU - Paolo Fagone AU - Eduard van Wijk AU - Yu Yan AU - Petra Schulz AU - Beate Ludescher AU - Michael Niedermaier AU - Joerg von Wegerer AU - Pia Rauch AU - Christian Setz AU - Ulrich Schubert AU - Wolfgang Brysch Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/04/2020.11.03.20216580.abstract N2 - At least since March 2020, the multiorgan disease COVID-19 has a firm grip on the world. Although most of the cases are mild, patients from risk populations could develop a cytokine storm, which is characterized by a systemic inflammatory response leading to acute respiratory distress syndrome and organ failure. The present paper will introduce the small molecule MP1032, describe its mode of action, and give rationale why it is a promising option for prevention/treatment of SARS-CoV-2-induced cytokine storm. MP1032 is a phase-pure anhydrous polymorph of 5-amino-2,3-dihydro-1,4-pthalazinedione sodium salt that exhibits good stability and bioavailability. The physiological action of MP1032 is based on a multi-target mechanism including localized, self-limiting antioxidant activities that were demonstrated in a model of lipopolysaccharide (LPS)-induced joint inflammation. Furthermore, immune-regulatory and PARP-1 modulating properties, coupled with antiviral effects against SARS-CoV-2 were shown in various cell models. Efficacy has been preclinically elucidated in LPS-induced endotoxemia, a model with excessively activated immune responses that shares many similarities to COVID-19. So far, during oral clinical development with three-months daily administrations, no serious adverse drug reactions occurred highlighting the outstanding safety profile of MP1032.Competing Interest StatementS.S., A.K., P.S., B.L., M.N., J.vW. are employees of MetrioPharm Deutschland GmbH F.N., K.M., P.F., E.vW., Y.Y., P.R., C.S. U.S. have nothing to disclose W.B. is employer, co-founder, and CEO of MetrioPharm AG The funders sponsored all the research but had no impact on the study results.Clinical TrialEudratCT-No: 2017-003484-36Funding StatementThis research did not receive any specific grant from funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical trial protocol was approved by the ethics committee of the State Chamber of Medicine in Rheinland-Pfalz (leading ethics committee in Germany; Internal file reference: 837.451.17 (11285)) and the ethics committee of the Country Medical Chamber in Rzeszow (leading ethics committee in Poland; Resolution No. 97/B/2017). The multi-center study was further approved by the German Federal Institute for Drugs and Medical Devices (BfArM,) Bonn (registration number 61-3910-4042376) and by the Polish President of The Office for Registration of Medical Products, Medical Devices and Biocidal Products, Warsaw (No. UR/DBL/D/044/2018). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author (SS).4-ANI4-amino-1,8-naphthalimideACE2Angiotensin-converting enzyme 2ARDSAcute respiratory distress syndromeCOVID-19Corona virus disease 2019CD4Cluster of differentiation 4DexDexamethasoneDMEMDulbecco’s Modified Eagle’s MediumELISAEnzyme-linked Immunosorbent AssayEtOHEthanolFCSFetal calf serumILInterleukinLPSLipopolysaccharidePARP-1Poly (ADP-ribose) polymerase 1PASIPsoriasis Area and Severity IndexPBMCPeripheral blood mononuclear cellsPBSPhosphate buffered salinePMPeritoneal macrophagesPMAPhorbol 12-myristate 13-acetateRFURelative fluorescence unitsROSReactive oxygen speciesSAESerious adverse eventSARS-CoV-2Severe acute respiratory syndrome coronavirus type 2SDS-PAGESodium dodecyl sulfate polyacrylamide gel electrophoresis SEM Standard error of the meanTEAETreatment-emergent adverse eventTNFαTumor necrosis factor-alphaUPEUltra-weak photon emissionWST-1Water-soluble tetrazolium salt 1 assay ER -